Full-Time

Expert Graphic Designer

Posted on 3/13/2025

Sanofi

Sanofi

10,001+ employees

Develops pharmaceuticals and vaccines globally

No salary listed

Expert

Hyderabad, Telangana, India

Category
3D Modeling
Animation
Visual Effects (VFX)
Graphic Design
Art, Graphics & Animation
Required Skills
Cinema 4D
Blender
Adobe Photoshop
Adobe After Effects
Adobe Illustrator
Video Editing
Graphic Design
Requirements
  • >10 years of experience in graphic design, video creation, web deliverables and new media
  • Must have strong hands-on experience with Blender / Maya / 3ds Max, Cinema 4D, Microsoft PowerPoint, Adobe Photoshop, Adobe Illustrator, Adobe InDesign, Adobe After Effects and Adobe Premier Pro
  • Should have knowledge of various useful plug-ins/ scripts of After Effects, Blender / Maya / 3ds Max for creating particle and fluid effects
  • Should have good handle on various style of art for 3D Motion graphics video creation (Low and High Poly style, Isometric style, trangulated poly style, toonish style, Abstract style)
  • Should be good in Modeling and Texturing
  • Should be able to create 3D assets for his assigned project
  • Should have good knowledge of Lighting and Rendering
  • Should be able to give beautiful look to final output
  • Ability to translate complex information in to a video
  • Ability to translate complex information to simple infographic or other allied easy ways to communicate visually
  • Ability to think creatively, aesthetically, independently and having excellent knowledge on all the graphic and current design trends
  • Experience / knowledge following brand guidelines while working on deliverables and preparing templates
  • Strong organizational and time management skills to effectively manage completing work activities
  • Good communication skills both verbal and written
  • Should be able to communicate clearly and effectively
  • Graduate or postgraduate in any stream. Primarily in graphic design or art with focus on visualization of scientific content
  • Excellent knowledge of English language (spoken and written)
Responsibilities
  • Deliver high quality designs from ideation through to completion within agreed timeline and guidelines
  • Design and produce creative deliverables like 3D video deliverables, medical training/educational videos, explainer videos, mechanism of action videos
  • Provide support on infographic animation, video publication articles, video editing, sound editing, promotional videos, animated icons, medical training PowerPoint slide decks, scientific posters, redrawing scientific images, interactive PPTs/PDFs, infographics, newsletters, e-mailers, flyers, brochures, e-learning modules, microsites and handouts
  • Maintain effective relationships with designers and Scientific Writers in Opella Science CoE and globally stakeholders
  • Provide technical support and guidance to graphic designers on deliverables as and when needed
  • Work on Complex/business-critical deliverables, primarily on publication materials
  • Extend support to work on digital and interactive deliverables based on the need
  • Collaborate primarily with other graphic designers and Opella Science CoE Scientific Writers to understand better on received project specific requirements
  • Act as an expert in the field of graphic design to provide technical support and guidance to graphic designers when needed
  • Proactively communicate and flag issues to Team Lead on project timelines
  • Prioritize and manage assigned projects; adhering to the defined quality and delivering on time
  • Using 3D modeling, texture, mapping, and other techniques to create graphics, visual effects, and animations
  • Creating storyboards to visualize scenes and create a realistic environment for scientific communication videos
  • Create and manage 3D digital assets for the assigned projects
  • Interpret concept art and sketches to create virtual characters, environment, and props
  • Creating Original Visual Assets for Video deliverables
  • Prototype and iterate on models and characters based on inputs received from Scientific Writers
  • Recreating real-world environments and layouts
  • Keep abreast with the latest developments in 3D design, capture and modeling tools and technologies
  • Assist in problem solving, suggesting best practices and seeking out new software, technologies and resources that will aid effective workflows
  • Design and set up new templates adhering to brand guidelines and manage the continuity
  • Ensure the quality of deliverables prepared by graphic designers are meeting Scientific Writers expectations
  • Constantly assist graphic designers in developing knowledge and sharing expertise
  • Actively participate in team meetings and provide suggestions based on the need for the team
  • Share best practices or any new learnings to the team
  • Show flexibility to meet project demands to deliver the output on-time
  • Explore opportunities to expand and support new types of deliverables
  • Indulge in self-learning in order to keep yourself updated with the latest developments in technologies required for the execution of work
Desired Qualifications
  • Desirable experience in pharmaceuticals / healthcare industry and scientific context mediation

Sanofi provides healthcare solutions through its pharmaceutical and biotechnology products, focusing on treatments and vaccines for various medical conditions. The company conducts extensive research and development to create new therapies and improve existing ones, particularly in areas like immunology, oncology, and rare diseases. Sanofi's products include prescription medicines, over-the-counter items, and vaccines, which are distributed to patients, healthcare professionals, and governments. What sets Sanofi apart from its competitors is its strong emphasis on scientific innovation and strategic partnerships, allowing it to maintain a diverse product pipeline. The company's goal is to enhance health outcomes and improve the quality of life for people globally by delivering effective and safe healthcare solutions.

Company Size

10,001+

Company Stage

IPO

Headquarters

Paris, France

Founded

1973

Simplify Jobs

Simplify's Take

What believers are saying

  • Sanofi's acquisition of Dren Bio enhances its biopharmaceutical capabilities.
  • Tolebrutinib's potential approval could revolutionize MS treatment with a novel mechanism.
  • Dupixent shows promise as a first targeted treatment for bullous pemphigoid.

What critics are saying

  • Increased competition from biosimilars threatens Sanofi's market share in key areas.
  • Geopolitical tensions in Eastern Europe may disrupt Sanofi's supply chain.
  • Scrutiny on drug pricing could pressure Sanofi's profitability.

What makes Sanofi unique

  • Sanofi's R&D focuses on unmet needs in immunology, oncology, and rare diseases.
  • The company has a robust pipeline of innovative vaccines and therapies.
  • Sanofi's global reach allows it to navigate diverse regulatory environments effectively.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Professional Development Budget

Parental Leave

Company News

PharmiWeb
Mar 25th, 2025
Tolebrutinib Regulatory Submission Accepted For Priority Review In The Us For Patients With Multiple Sclerosis

If approved, tolebrutinib would be the first and only brain-penetrant BTK inhibitor to both treat non-relapsing secondary progressive multiple sclerosis (MS) and slow disability accumulation independent of relapse activityTolebrutinib has the potential to be the first therapy to target smoldering neuroinflammation, a key driver of disability accumulation in MSTolebrutinib was granted breakthrough therapy designation by the FDA based on positive results from the HERCULES phase 3 study in adults with non-relapsing secondary progressive MSParis, March 25, 2025. The US Food and Drug Administration (FDA) is evaluating under priority review the regulatory submission of tolebrutinib to treat non-relapsing secondary progressive multiple sclerosis (nrSPMS) and to slow disability accumulation independent of relapse activity in adult patients. The target action date for the FDA decision is September 28, 2025. A regulatory submission is also under review in the EU.The regulatory submissions in the US and the EU are supported by the results from the phase 3 studies HERCULES in nrSPMS and GEMINI 1 and 2 in relapsing MS (RMS). The findings from these studies, as well as additional clinical and preclinical studies, support the differentiated mechanism of tolebrutinib to target disability progression independent of relapse activity, and the scientific hypothesis that smoldering neuroinflammation represents a key inflammatory process in MS and is a critical driver of disability accumulation.Erik Wallström, MD, PhDGlobal Head of Neurology Development“The totality of data across our clinical program validates our scientific understanding of smoldering neuroinflammation as a distinct inflammatory process in MS. People living with non-relapsing secondary progressive multiple sclerosis or who experience disability independent of relapse activity suffer from disability that worsens over time due to persistent inflammation in the brain, known as smoldering neuroinflammation, which is the primary driver of disability

PharmiWeb
Mar 25th, 2025
Availability Of The Q1 2025 Aide Mémoire

Paris, France – March 24, 2025. Sanofi announced today that its Q1 2025 Aide mémoire is available on the "Investors" page of the company's website:First quarter 2025 (sanofi.com)As for each quarter, Sanofi prepared this document to assist in the financial modelling of the Group's quarterly results. This document includes a reminder on various non-comparable items and exclusivity losses as well as the foreign currency impact and share count. Sanofi's first quarter 2025 results will be published on April 24, 2025.About SanofiWe are an innovative global healthcare company, driven by one purpose: we chase the miracles of science to improve people’s lives. Our team, across some 100 countries, is dedicated to transforming the practice of medicine by working to turn the impossible into the possible. We provide potentially life-changing treatment options and life-saving vaccine protection to millions of people globally, while putting sustainability and social responsibility at the center of our ambitions.Sanofi is listed on EURONEXT: SAN and NASDAQ: SNYMedia RelationsSandrine Guendoul | + 33 6 25 09 14 25 | [email protected] Berland | + 1 215 432 0234 | [email protected] Obrist | + 33 6 77 21 27 55 | [email protected]éo Le Bourhis | + 33 6 75 06 43 81 | [email protected] Rouault | + 33 6 70 93 71 40 | [email protected] Gilbert | + 1 516 521 2929 | [email protected] RelationsThomas Kudsk Larsen | + 44 75 45 51 36 93| [email protected]é Kaisserian | + 33 6 47 04 12 11 | [email protected] Lauscher | + 1 908 612 7239 | [email protected] Browne | +1 781 249 1766 | [email protected] Pham | + 33 7 85 93 30 17 | [email protected] Elgoutni | + 1 617 710 3587 | [email protected] Châtelet | + 33 6 80 80 89 90 | [email protected] Li | + 33 6 84 00 90 72 | [email protected] statementsThis press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended

BNE
Mar 20th, 2025
Serbian biotech Dren Bio sold to Sanofi for $1.9bn

Pharma-major Sanofi has acquired Serbian-founded biopharmaceutical company Dren Bio for up to $1.9bn, the companies announced in a press release on ...

PharmiWeb
Mar 10th, 2025
Dupixent Late-Breaking Positive Pivotal Data In Bullous Pemphigoid Presented At Aad

Five times more adults on Dupixent achieved sustained disease remission at 36 weeks compared to placebo; significant reductions were also seen in disease severity and itchDupixent also significantly reduced oral corticosteroid and rescue medicine use compared to placeboData support the potential of Dupixent to be the first and only targeted medicine to treat bullous pemphigoid, a skin disease with underlying type 2 inflammation; regulatory submissions are under review in the US and the EUParis and Tarrytown, NY, March 8, 2025. Positive results from the pivotal ADEPT phase 2/3 study evaluating the investigational use of Dupixent (dupilumab) in adults with moderate-to-severe bullous pemphigoid (BP) were shared in a late-breaking oral presentation at the 2025 American Academy of Dermatology (AAD) Annual Meeting. BP is a chronic, debilitating, and relapsing skin disease with underlying type 2 inflammation and characterized by intense itch and blisters, reddening of the skin, and painful lesions.Victoria Werth, MDChief of the Division of Dermatology at the Philadelphia Veterans Administration Hospital, Professor of Dermatology and Medicine at the Hospital of the University of Pennsylvania and the Veteran's Administration Medical Center, and principal investigator of the study“People with bullous pemphigoid live with unrelenting itch, blisters, and painful lesions that can be debilitating and make it difficult to function daily. Moreover, current treatment options can be challenging for this primarily elderly patient population because they work by suppressing their immune system. By targeting the underlying type 2 inflammation, which is a key driver for bullous pemphigoid, Dupixent is the first investigational biologic to show sustained disease remission and reduce disease severity and itch compared to placebo in a clinical study.”The ADEPT study met all primary and key secondary endpoints, enrolling 106 adults with moderate-to-severe BP who were randomized to receive Dupixent 300 mg (n=53) every two weeks after an initial loading dose or placebo (n=53) added to standard-of-care oral corticosteroids (OCS). During treatment, all patients underwent a protocol-defined OCS tapering regimen if control of disease activity was maintained

Sanofi
Mar 7th, 2025
Press release: Sanofi successfully prices EUR 1.5 billion of bond issue

Sanofi successfully prices EUR 1.5 billion of bond issue  Paris, March 5, 2025. Sanofi announces that it has successfully priced its offering of EUR 1.5 billion of notes across 2 tranches: €850...

INACTIVE